Liver cancer trial tests immunotherapy plus chemo combo
NCT ID NCT06860490
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing whether adding a targeted chemotherapy infusion into the liver (HAIC) to a combination of two drugs—sintilimab (an immunotherapy) and bevacizumab biosimilar (which blocks blood vessel growth)—helps people with advanced liver cancer live longer without their disease getting worse. The study plans to enroll 164 participants who have not had prior systemic therapy. Researchers will compare the group receiving all three treatments against those getting only the two drugs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sintilimab (an immunotherapy drug) and bevacizumab biosimilar (a drug that blocks blood vessel growth), with or without HAIC (chemotherapy delivered directly to the liver via a catheter)
- What this could lead to
- If successful, this could point toward a more effective combination treatment for advanced liver cancer that has not been treated before.
- What could go wrong
- This is a mid-stage (Phase 2) trial with only 164 people, so results may not apply to everyone. Adding HAIC may increase side effects without clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test
- Can a triple therapy shrink untreatable liver tumors?